Erratum: Cost-effective evaluation of nonalcoholic fatty liver disease with nafld fibrosis score and vibration-controlled transient elastography (American Journal of Gastroenterology (2015) 110 (1298-1304) DOI: 10.1038/ajg.2015.241));Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease with NAFLD Fibrosis Score and Vibration Controlled Transient Elastography

American Journal of Gastroenterology

Volumn 110, Issue 9, 2015, Pages 1298-1304

  Tapper, Elliot B ^a   Sengupta, Neil ^a   Hunink, M G Myriam ^b,c   Afdhal, Nezam H ^a   Lai, Michelle ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; ELASTOGRAPHY; FEMALE; GASTROENTEROLOGIST; HUMAN; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY; BIOPSY; COST BENEFIT ANALYSIS; ECONOMICS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROCEDURES; SEVERITY OF ILLNESS INDEX; VIBRATION;

BIOPSY; COST-BENEFIT ANALYSIS; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; VIBRATION;

EID: 84941260556     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.14     Document Type: Erratum

References (33)

1. Afdhal NH. Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both? JAMA 2012; 308: 608-16.
2. Chalasani N, Younossi Z, Lavine JE et al. Th e diagnosis and management of non alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastro enterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
3. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999-2006. Diabetes care 2011; 34: 216-9.
4. Peery AF, Dellon ES, Lund J et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-87.
5. Pasha T, Gabriel S, Th erneau T et al. Cost eff ectiveness of ultrasoundguided liver biopsy. Hepatology 1998; 27: 1220-6.
6. Rockey DC, Caldwell SH, Goodman ZD et al. Liver biopsy. Hepatology 2009; 49: 1017-44.
7. Foster G, Goldin R, Main J et al. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ 1997; 315: 453-8.
8. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fi brosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
9. Angulo P, Hui JM, Marchesini G et al. Th e NAFLD fi brosis score: a noninvasive system that identifi es liver fi brosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
10. Dowman JK, Tomlinson J, Newsome P. Systematic review: the diagnosis and staging of non alcoholic fatty liver disease and non alcoholic steatohepatitis. Aliment Pharmacol Th er 2011; 33: 525-40.
11. McPherson S, Stewart SF, Henderson E et al. Simple non-invasive fi brosis scoring systems can reliably exclude advanced fi brosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-9.
12. Petta S, Vanni E, Bugianesi E et al. Th e combination of liver stiff ness measurement and NAFLD fi brosis score improves the noninvasive diagnostic accuracy for severe liver fi brosis in patients with nonalcoholic fatty liver disease. Liver Int 2014; 35: 1566-73.
13. Tapper EB, Castera L, Afdhal NH. FibroScan (vibration controlled transient elastography): where does it stand in the US practice. Clin Gastroenterol Hepatol 2014; 13: 27-36.
14. Hunink MGM, Wienstein MC, Wittenberg E et al. Decision Making in Health and Medicine: Integrating Evidence and Values Cambridge University Press: Cambridge, UK, 2014.
15. Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ 2011; 342: 1-6.
16. Siegel JE, Weinstein MC, Russell LB et al. Recommendations for reporting cost-eff ectiveness analyses. JAMA 1996; 276: 1339-41.
17. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
18. Adams LA, Sanderson S, Lindor KD et al. Th e histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-8.
19. Dixon JB, Bhathal PS, Hughes NR et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-54.
20. Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the eff ects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-9.
21. Sabate E. Adherence to Long-Term Th erapies: Evidence for Action World Health Organization: 2003.
22. Tapper EB, Krajewski K, Lai M et al. Simple non-invasive biomarkers of advanced fi brosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf) 2014; 2: 276-80.
23. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
24. de Ledinghen V, Wong VW-S, Vergniol J et al. Diagnosis of liver fi brosis and cirrhosis using liver stiff ness measurement: comparison between M and XL probe of FibroScan. J Hepatol 2012; 56: 833-9.
25. Kwok R, Tse YK, Wong GH et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Th er 2014; 39: 254-69.
26. Wong VW-S, Vergniol J, Wong GL-H et al. Liver stiff ness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107: 1862-71.
27. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-eff ectiveness-the curious resilience of the 50,000-per-QALY threshold. N Engl J Med 2014; 371: 796-7.
28. Canavan C, Eisenburg J, Meng L et al. Ultrasound elastography for fi brosis surveillance is cost eff ective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013; 58: 2691-704.
29. Tsochatzis EA, Crossan C, Longworth L et al. Cost-eff ectiveness of noninvasive liver fi brosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology 2014; 60: 832-43.
30. Steadman R, Myers RP, Leggett L et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol 2013; 27: 149.
31. Myers RP, Pomier-Layrargues G, Kirsch R et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiff ness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.
32. Afdhal NH, Bacon BR, Patel K et al. Accuracy of Fibroscan, compared with histology, in analysis of liver fi brosis in patients with Hepatitis B or C: a US multi-center study. Clin Gastroenterol Hepatol 2014; 13: 772-9.
33. de Ledinghen V, Vergniol J, Capdepont M et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 2014; 60: 1026-31.